预约演示
更新于：2026-07-07
Pregabalin
普瑞巴林
更新于：2026-07-07
概要
基本信息
简介普瑞巴林，商品名为 Lyrica®，是一种众所周知的抗惊厥药物，已在各种疾病的治疗中找到立足之地。 这些病症包括但不限于焦虑症、癫痫和神经痛。普瑞巴林的作用机制包括阻断 CACNA2D1、CACNA2D2钙通道，从而有效地治疗这些疾病。Upjohn Co. 早在 2004 年就在欧盟获得了普瑞巴林的医疗用途批准，并已在市场上应用。普瑞巴林的适应症主要针对神经性疼痛病症如纤维肌痛，与其他抗惊厥药物联合用于治疗部分发作性癫痫。由于普瑞巴林可最大限度地减少伴随症状，因此可以使用普瑞巴林来控制这些病症。 因此，普瑞巴林是治疗慢性疼痛和神经系统疾病的重要措施。 |
药物类型 小分子化药 |
别名 LYRICA CR、CI-1008、GLA5PR + [13] |
作用方式 阻滞剂 |
作用机制 CACNA2D1阻滞剂(电压门控性钙通道α2/δ亚基-1阻滞剂)、CACNA2D2阻滞剂(电压门控性钙通道α2/δ亚基-2阻滞剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C8H17NO2 |
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N |
CAS号148553-50-8 |
关联
1,075
项与 普瑞巴林 相关的临床试验NCT07549490
A Pilot Study for Developing a Comprehensive Signal Detection Approach for the Mechanisms of Action and Analgesic Efficacy of Two Analgesics Using Human Experimental Models of Pain (HEMP)
NCT07618715
An Open-label, Single-dose, Three-period Phase Ⅰ Study to Compare the Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
CTIS2024-518824-56-00
Pregabalin or Baclofen in Spastic Motor Behavior Treatment After SCI (PoBSCI), Prospective, Double-Blind, Randomised Drug Study
100 项与 普瑞巴林 相关的临床结果
登录后查看更多信息
100 项与 普瑞巴林 相关的转化医学
登录后查看更多信息
100 项与 普瑞巴林 相关的专利（医药）
登录后查看更多信息
5,945
项与 普瑞巴林 相关的文献（医药）2026-12-31COPD-Journal of Chronic Obstructive Pulmonary Disease
Prescribing Patterns of Gabapentinoids in Patients with Chronic Obstructive Pulmonary Disorder
Article
作者: Bullock, Reece ; Dimit, Alexandra ; Patel, Manysha ; Englehart, Anika ; King, Olivia ; Soric, Mate Michael ; Bole, Kelly ; Mara, Nita ; Vergara, Mollie ; Moqbl, Amgad ; Skory, Brandon
In 2019, the U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of serious respiratory depression in patients using gabapentin or pregabalin who have respiratory risk factors, including those with chronic obstructive pulmonary disorder (COPD). With the overall prescribing of gabapentinoids continuing to grow, there is the potential for inappropriate prescribing in this patient population. Data from the National Ambulatory Medical Care Survey (NAMCS) from 2013 to 2018, with the exception of 2017, was used to assess prevalence and predictors of gabapentinoid prescribing in patients with COPD. The data consists of 1,131 unweighted visits, representing approximately 53.6 million ambulatory care visits nationally. Of these visits, 146 patients (10.8%) with a COPD diagnosis were also prescribed a gabapentinoid, which represents more than a million office visits annually when weighted. Patients with an increased risk of receiving gabapentinoids were those with concomitant diabetes mellitus, concurrent opioid use, and those currently using tobacco. Due to increased risk of serious respiratory depression caused by gabapentinoids, prescribers should take caution when prescribing to individuals with COPD and other respiratory risk factors. Based on the reviewed prescribing patterns, more education is needed to inform providers about the risks associated with concomitant COPD and gabapentinoid use.
2026-07-01EUROPEAN JOURNAL OF PAIN
Changes in Gabapentinoid Use Among Danish Patients With Spinal Pain: A Comparison of Two Secondary Care Cohorts 2013–2014 and 2021–2022
Article
作者: Hansen, Anders ; Nim, Casper ; Ziegler, Dorthe S. ; Hartvigsen, Jan ; Clausen, Stine ; Skovsgaard, Christian V.
ABSTRACT:
Background:
Gabapentinoids (gabapentin and pregabalin) are increasingly prescribed for spinal pain despite limited evidence of benefit and recognised risks. Understanding which characteristics influence prescribing and how prescription use has evolved may inform safer and more evidence‐based practice.
Objectives:
To compare determinants of gabapentinoid use and changes over time between two separate cohorts of patients referred to the Spine Centre of Southern Denmark.
Methods:
Our study comprised two cohorts: the first, from 2013 to 2014 (
n
= 16,732), and the second, from 2021 to 2022 (
n
= 13,939). Redeemed gabapentinoid prescriptions were assessed within a 12‐month window (6 months before and after the spine centre index date) and linked with diagnostic, socioeconomic and patient‐reported information. Patients were categorised as continued users, initiators, discontinuers or non‐users using a ≥ 30 defined daily dose classification threshold to distinguish sporadic from more sustained dispensing. Multinomial logistic regression, incorporating demographic, socioeconomic and clinical covariates, identified characteristics associated with use.
Results:
Gabapentinoid use more than doubled from Cohort 1 to Cohort 2, with continued users increasing from 2.4% to 6.6% and initiators increasing from 3.5% to 6.1%. Radiculopathy, higher disability and concurrent opioid or weak analgesic use showed the strongest positive associations with use across both cohorts.
Conclusions:
Gabapentinoid use for patients with spinal pain attending secondary care in Denmark increased substantially across the decade, despite only modest differences in patient characteristics. Gabapentinoid use remained concentrated among patients with radiculopathy and concurrent analgesic use, underscoring continued reliance on pharmacological management.
Significance Statement:
This study identifies a marked rise in gabapentinoid prescribing for spinal pain in secondary care and shows that the increase was only partly explained by differences in patient characteristics. The findings highlight continued use in patient groups where clinical benefit remains unproven, reinforcing the need for safer, more evidence‐based prescribing strategies.
2026-07-01FORENSIC SCIENCE INTERNATIONAL
Investigation of the utility of vitreous humour drug concentrations when compared to peripheral blood using the National Programme on Substance Use Mortality database
Article
作者: Morley, S R ; Copeland, C S
Peripheral blood (PB) remains the standard matrix for postmortem toxicological analysis, yet its interpretive reliability is often compromised by postmortem redistribution (PMR), trauma, or decomposition. Vitreous humour (VH), due to its anatomical isolation and reduced susceptibility to PMR, has emerged as a promising alternative matrix. This study investigates the correlation between VH and PB drug concentrations using data from the National Programme on Substance Use Mortality (NPSUM), aiming to enhance interpretive accuracy and forensic utility of VH. A total of 110 cases with paired VH and PB drug concentrations were identified. Quantitative toxicology data were extracted from coronial submissions across the UK, with analysing laboratories accredited by UKAS or an international equivalent. Statistical comparisons were performed using Wilcoxon signed-rank tests and coefficients of determination (R²) to assess correlation strength. Drug concentrations were consistently lower in VH than PB, yet all drugs detected in PB were also present in VH. Strong correlations were observed for pregabalin (R²=0.86), methadone (R²=0.81), gabapentin (R²=0.76), and codeine (R²=0.70), while cocaine (R²=0.56) showed moderate correlation. Weak correlations were noted for BZE (R²=0.44), EDDP (R²=0.20), and morphine (R²=0.19). These findings suggest that VH concentrations reflect systemic levels for certain drugs, particularly those with limited PMR and favourable physicochemical properties. The study highlights VH's value as a confirmatory matrix, especially when PB is unavailable. However, the variability in VH-PB correlations underscores the need for matrix-specific interpretive frameworks. Factors such as lipophilicity, protein binding, and molecular size appear to influence VH penetration more than PMR alone. This work represents one of the most comprehensive evaluations of VH-PB drug correlations to date and supports the development of a systematic reference database. Future research should expand case numbers and incorporate additional covariates to refine VH-based interpretive models. VH offers a viable alternative for postmortem toxicology, but its evidential weight depends on drug-specific characteristics and robust reference data.
100 项与 普瑞巴林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 纤维肌痛 | 韩国 | 2005-06-14 | |
| 癫痫发作 | 澳大利亚 | 2005-04-13 | |
| 糖尿病周围神经病变 | 美国 | 2004-12-30 | |
| 疱疹后神经痛 | 美国 | 2004-12-30 | |
| 疱疹后神经痛 | 美国 | 2004-12-30 | |
| 癫痫部分性发作 | 欧盟 | 2004-07-05 | |
| 癫痫部分性发作 | 冰岛 | 2004-07-05 | |
| 癫痫部分性发作 | 列支敦士登 | 2004-07-05 | |
| 癫痫部分性发作 | 挪威 | 2004-07-05 | |
| 癫痫 | 欧盟 | 2004-07-05 | |
| 癫痫 | 冰岛 | 2004-07-05 | |
| 癫痫 | 列支敦士登 | 2004-07-05 | |
| 癫痫 | 挪威 | 2004-07-05 | |
| 广泛性焦虑障碍 | 欧盟 | 2004-07-05 | |
| 广泛性焦虑障碍 | 冰岛 | 2004-07-05 | |
| 广泛性焦虑障碍 | 列支敦士登 | 2004-07-05 | |
| 广泛性焦虑障碍 | 挪威 | 2004-07-05 | |
| 神经痛 | 欧盟 | 2004-07-05 | |
| 神经痛 | 冰岛 | 2004-07-05 | |
| 神经痛 | 列支敦士登 | 2004-07-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下肢溃疡 | 临床3期 | 美国 | 2015-05-15 | |
| 幻肢 | 临床3期 | 美国 | 2015-05-15 | |
| 难治性慢性咳嗽 | 临床3期 | 澳大利亚 | 2012-02-28 | |
| 强直阵挛性癫痫 | 临床3期 | 美国 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 中国 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 白俄罗斯 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 比利时 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 保加利亚 | 2012-02-21 | |
| 强直阵挛性癫痫 | 临床3期 | 捷克 | 2012-02-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 151 | 構觸壓餘繭願鏇餘淵鬱(獵膚網繭鑰壓蓋衊衊繭) = 繭窪淵糧壓鏇簾衊繭壓 選築鏇鬱範憲築簾蓋齋 (餘憲獵製窪鹽餘艱構糧, 18.94) | 积极 | 2026-07-01 | |||
- | |||||||
N/A | 164 | 襯鏇齋鏇鬱鑰憲鬱襯網(製顧窪糧鏇艱廠築築構) = 鬱網廠積遞廠顧餘憲顧 醖繭窪夢願醖廠壓鏇膚 (獵糧鹹夢夢醖範窪糧廠 ) | 积极 | 2026-05-01 | |||
襯鏇齋鏇鬱鑰憲鬱襯網(製顧窪糧鏇艱廠築築構) = 選餘膚窪餘鬱膚鏇壓獵 醖繭窪夢願醖廠壓鏇膚 (獵糧鹹夢夢醖範窪糧廠 ) | |||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 願淵簾夢鏇膚窪廠齋齋(鑰築願鑰廠觸廠憲鏇糧) = 淵繭築觸淵窪選遞遞衊 網製醖繭衊膚窪壓願壓 (築襯膚選艱鹽艱鹽衊遞, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 願淵簾夢鏇膚窪廠齋齋(鑰築願鑰廠觸廠憲鏇糧) = 淵遞鹹膚鏇蓋選襯顧顧 網製醖繭衊膚窪壓願壓 (築襯膚選艱鹽艱鹽衊遞, 1.6) 更多 | ||||||
临床4期 | 109 | (Pregabalin) | 選鹹鬱齋繭糧窪壓鹽醖(鹽壓膚壓餘觸襯蓋鬱遞) = 蓋艱鹹觸積壓齋壓醖選 餘鑰憲鏇壓鏇築構願鬱 (顧積鑰網齋鹹繭簾積願, 窪網繭糧艱憲簾鑰鹽醖 ~ 簾醖築餘齋糧艱糧鏇願) 更多 | - | 2026-01-06 | ||
(Gabapentin) | 選鹹鬱齋繭糧窪壓鹽醖(鹽壓膚壓餘觸襯蓋鬱遞) = 廠壓製鑰糧鏇製鏇壓壓 餘鑰憲鏇壓鏇築構願鬱 (顧積鑰網齋鹹繭簾積願, 夢獵夢鹽淵夢齋鬱襯鏇 ~ 觸構餘簾構鑰積艱構鏇) 更多 | ||||||
N/A | 179,684 | 獵衊夢鬱衊鬱糧夢壓鹹(衊糧顧觸餘簾鑰鏇觸簾): HR = 1.23 (95.0% CI, 1.08 ~ 1.4) 更多 | 不佳 | 2025-10-24 | |||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 遞願觸襯糧觸積鬱壓膚(構簾糧糧範夢襯蓋鑰鏇) = 製齋鬱簾襯窪鹹鏇蓋襯 淵選鏇膚獵蓋選製艱鹽 (築蓋遞願構鹽鏇艱夢醖, 淵醖築壓襯顧鹽窪糧積 ~ 範選鏇蓋獵獵網廠製蓋) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 遞願觸襯糧觸積鬱壓膚(構簾糧糧範夢襯蓋鑰鏇) = 獵築廠製築鏇獵衊襯淵 淵選鏇膚獵蓋選製艱鹽 (築蓋遞願構鹽鏇艱夢醖, 鑰選構顧鹹齋醖餘糧觸 ~ 鏇夢窪窪製鬱襯鏇積餘) 更多 | ||||||
N/A | 179,562 | 糧膚蓋獵願醖製積鹹顧(憲糧網鬱餘醖繭衊窪築) = 淵憲鏇淵範範範鬱夢鏇 願積淵淵餘鹹構憲鹹顧 (餘網願壓範壓選廠夢網 ) | 不佳 | 2024-11-10 | |||
糧膚蓋獵願醖製積鹹顧(憲糧網鬱餘醖繭衊窪築) = 艱醖獵壓觸獵齋齋壓衊 願積淵淵餘鹹構憲鹹顧 (餘網願壓範壓選廠夢網 ) | |||||||
临床2/3期 | 118 | (Pregabalin 300mg) | 願鹹餘齋鏇蓋鏇醖遞餘(網夢選夢簾窪網願鹹製) = 鏇齋鬱構廠鏇憲壓廠廠 蓋憲齋廠艱願簾鬱鹹齋 (鏇觸築襯繭襯製積淵廠, 簾窪憲醖繭餘選鹽襯膚 ~ 窪簾築鹹餘積鹹廠襯選) 更多 | - | 2024-10-24 | ||
Placebo oral tablet (Placebo) | 願鹹餘齋鏇蓋鏇醖遞餘(網夢選夢簾窪網願鹹製) = 觸淵糧醖積遞顧觸簾廠 蓋憲齋廠艱願簾鬱鹹齋 (鏇觸築襯繭襯製積淵廠, 觸鏇蓋齋簾醖淵願選願 ~ 願鹹鹽糧鏇獵願繭築壓) 更多 | ||||||
临床4期 | 130 | Sustained-Release Pregabalin 150 mg | 夢範顧築壓築鑰鑰鹹鹽(繭糧糧網觸遞觸鹹窪醖) = 蓋廠繭糧築膚網網獵壓 襯構鏇醖齋蓋醖壓醖觸 (膚窪蓋鬱壓膚醖醖繭齋 ) | 积极 | 2024-07-14 | ||
Immediate-Release Pregabalin 75 mg | 夢範顧築壓築鑰鑰鹹鹽(繭糧糧網觸遞觸鹹窪醖) = 鏇願願鏇襯齋範築夢鏇 襯構鏇醖齋蓋醖壓醖觸 (膚窪蓋鬱壓膚醖醖繭齋 ) | ||||||
临床4期 | - | 100 | (Multi-modal) | 餘衊繭觸膚觸築觸艱餘(範膚範網構築築夢餘憲) = 構構選糧糧齋獵構壓壓 鹹艱鬱膚簾齋觸淵淵夢 (觸選膚艱膚鬱夢構製網, 壓觸糧願窪廠廠蓋衊顧 ~ 鑰淵觸製蓋遞醖遞糧網) 更多 | - | 2024-07-08 | |
(Control) | 餘衊繭觸膚觸築觸艱餘(範膚範網構築築夢餘憲) = 繭夢積簾鹽襯獵淵網夢 鹹艱鬱膚簾齋觸淵淵夢 (觸選膚艱膚鬱夢構製網, 構窪鬱餘蓋壓鹽膚鬱蓋 ~ 構廠蓋鏇鬱衊範鏇簾觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用